论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
嵌合抗原受体 T 细胞治疗卵巢癌的研究进展
Authors Yan W, Hu H, Tang B
Received 30 January 2019
Accepted for publication 10 September 2019
Published 30 September 2019 Volume 2019:12 Pages 8015—8022
DOI https://doi.org/10.2147/OTT.S203550
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Ms Rachel Predeepa
Peer reviewer comments 2
Editor who approved publication: Dr Faris Farassati
Abstract: Ovarian cancer, as a common gynecological tumor, is currently recognized as the most lethal gynecological malignancy. In addition to conventional treatment methods such as surgery, radiotherapy and chemotherapy, adoptive immunotherapy represented by modified immune cells also shows good curative effects and is becoming an important method in the treatment of ovarian cancer. Studies have shown that most cancer cells can avoid the recognition of the immune system, thus limiting the anticancer effect of immunotherapy. Chimeric antigen receptor T (CAR-T) cell technology has emerged and has good targeting, killing, proliferation and persistence. A large number of clinical trials also have shown that this technology has achieved great success in improving the quality of life and prolonging the survival time of patients with malignant hematological tumors. CAR-T cell technology has become a research hotspot for immunotherapy. This article mainly reviews various CAR-T cell treatments and their specific mechanisms in the field of ovarian cancer treatment to provide new ideas for the treatment of ovarian cancer.
Keywords: immunotherapy, T cell, ovarian cancer, chimeric antigen receptor, tumor antigens